Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.

Toshinari YamashitaJoo Hyuk SohnEriko TokunagaNaoki NiikuraYeon Hee ParkKeun Seok LeeYee Soo ChaeBinghe XuXiaojia WangSeock-Ah ImWei LiYen-Shen LuCecilia Orbegoso AguilarSoichiro NishijimaYuji NishiyamaMasahiro SugiharaShanu ModiJunji Tsurutani

Published in: Breast cancer (Tokyo, Japan) (2024)

ClinicalTrials.gov, NCT03734029.

Keyphrases

metastatic breast cancer
emergency department
primary care
clinical trial
epidermal growth factor receptor
locally advanced
squamous cell carcinoma
newly diagnosed
liver metastases
decision making
phase iii
study protocol
double blind